Hany Elmariah, MD, discusses how he sees fedratinib fitting into clincal practice for the treatment of myeloproliferative neoplasms.

Panelists discuss how advancements in understanding myeloproliferative neoplasms are shaping treatment approaches through case studies of intermediate-risk myelofibrosis and advanced polycythemia vera ...

Protagonist Therapeutics, Inc.’s PTGX share price has surged by 6.71%, which has investors questioning if this is right time to sell.